HealthyNCT07008586
The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans.
A study testing OliPhenolia® in people with Healthy, run by Anglia Ruskin University at 1 site in United Kingdom.
Trial summary
This research proposal follows on from previously undertaken work investigating a commercially available olive derived product (OliPhenolia®) on potential exercise / functional benefits for healthy adults. Read more about this study
- Who is it for?
- Ages 21 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- OliPhenolia®
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 18 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Jul 2025to 10 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age ≥ 21 in line with manufacturer recommendations.
- Written informed consent.
- Willingness and ability to conform to the full protocol (please see full protocol).
- Judged by the investigator to be in good health.
- To have a pre-study health screen signed off by the lead researcher.
Who cannot join
- Current or recent (within the last 4 weeks) engagement with a strict dietary regime i.e., vegetarian / vegan / ketogenic / paleolithic / high protein / weight loss.
- Any known issues with blood taking.
- Any known bleeding disorders.
- Any known allergy to olives, grapes, lemon, coca cola or prunes.
- Average alcohol use of <21 glasses per week for men and <14 glasses per week for women (on average for the last six months).
- Any drug or medicine abuse in the last six months
Show all 14Show fewer
- Known cardiovascular disease, disease related to the immune system (including HIV and hepatitis) and / or the respiratory system.
- Known Diabetes Mellitus type I or type II.
- Known renal or liver issues or known thyroid dysfunction.
- Currently undertaking regular heavy and / or extreme exercise (please discuss with the lead researcher if you are unsure).
- Current smoker or stopped smoking for <one month prior to the first visit.
- Current participation in any other clinical study within the month previous to the study start date (discuss with the lead researcher if unsure).
- Known pregnancy and / or lactation (women only)
- Uncertainty about the willingness or ability of the subject to comply with the protocol requirements.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University,
Cambridge, CB5 8DZ
About this study
Official title: The Acute and Chronic Effects of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Healthy Adult Humans.
This research proposal follows on from previously undertaken work investigating a commercially available olive derived product (OliPhenolia®) on potential exercise / functional benefits for healthy adults. Previous research investigated a dose response bioavailability of the main polyphenol in OliPhenolia® and related metabolites. Based on this data, the current study will aim to investigate, for the first time, whether the polyphenols in the product can positively influence exercise specific inflammation which may be pertinent to improving exercise recovery and is of current scientific interest. As such this research aims to understand the short term (Phase 1) and longer term (Phase 2) use of OliPhenolia® on acute recovery from a standard exercise bout.
Research questions:
Read more
- Does an acute dose of OliPhenolia® reduce exercise associated inflammation markers and enhance functional recovery in healthy adult humans?
- Does a consecutive 16 day intake of OliPhenolia® reduce exercise associated inflammation markers and enhance functional recovery in healthy adult humans?
- Does a continued intake of OliPhenolia® during the recovery period after the exercise bout further amplify functional benefits compared experimental control?
Proposed methodology:
Phase 1 - To answer research question 1, following a randomisation procedure, participants will be allocated product (OliPhenolia®) or colour and taste matched placebo. A single serve of product (no more than 1.5 mg/kg of hydroxytyrosol (HT) via OliPhenolia®) or placebo will be provided ~40 minutes prior to a standardised exercise protocol. Resting wholeblood samples will be collected at 0 (baseline) +1, +24, +48 and +72 hours following the exercise bout to identify the impact of an acute dose of OliPhenolia® has on selected inflammatory biomarkers. This phase will be a placebo-controlled crossover design and therefore after a ≥7 day wash out period, participants will return to the exercise laboratory (Compass House Human Physiology laboratories, Anglia Ruskin University, Cambridge), supplement the alternate product and repeat the experimental protocol as outlined above.
Phase 2 - To answer research question 2, having completed Phase 1 (and following another ≥7 day wash out period), all participants will continue onto Phase 2, maintaining their previously assigned product, but this time will continue supplementation for 16 consecutive days. Phase 2 is therefore a parallel placebo-controlled design that focusses on a chronic supplementation of OliPhenolia®. Participants will consume one serve of either product or placebo twice daily for 16 days. After 16 days of supplementation participants will return to the exercise laboratory, and in the same manner as Phase 1, consume a single dose of their assigned product or placebo ~ 40 minutes prior to the standardised exercise protocol. Resting wholeblood samples will be collected following exercise at baseline, +1, +24, +48 and +72 hours.
To answer research question 3, all participants will be informed that they may be asked to consume an additional three days supplementation in a random manner (total 19 days). To limit participant burden 50 % of the experimental group (those that have been supplementing OliPhenolia®) and placebo group will continue supplementing two doses daily for the three days following the standardised exercise protocol (the three days where blood samples occur) in order to understand if a sustained course of OliPhenolia® can reduce the time taken for inflammatory mediators to return to baseline values.
Read the detailed description
Following the current scientific interest surrounding the application of polyphenols in an exercise domain, the primary objectives of this research will build upon previously published work investigating polyphenol rich olive fruit water by identifying the acute and chronic effect of OliPhenolia® on inflammation and functional mobility following exercise induced inflammation. For the purpose of this research, the impact on inflammation will be investigated via the measurements of biomarkers Interleukin (IL)-6, IL-1ra, and Transforming growth factor-beta. Additionally, lactate dehydrogenase (a marker of muscle damage) and superoxide dismutase (a marker of oxidative stress) will also be measured to confirm the source and impact of the exercise induced inflammation. Furthermore, for the purpose of this research, a functional movement screen, localised goniometry and algometry will be measured surrounding the standardised exercise protocol to assess the impact of OliPhenolia on functional mobility. Within this study, participants will be required to attend a pre-screening and familiarisation session followed by three separate trials. Each trial, separated by a ~7 day wash out period will consist of four visits. The first visit (estimated duration 3 hours) will include the baseline resting venepuncture blood sample (0), basic physiological, anthropometric and cognitive assessments, standardised exercise protocol, post exercise blood sample (+1 hour) and post exercise physiological assessment. The standardised exercise protocol that will take place 40 minutes after the supplementation of OliPhenolia is as follows: A maximum of six sets of 25 drop jumps wearing a weighted vest (7.5% body mass) from a height of 60 cm with a maximum 10 second interval between jumps and a 1 min passive rest between sets (modified from Kirby et al., 2011). The following three visits (estimated duration 45 minutes) will take place over the following three days and require a resting venepuncture blood sample (+24 hours, +48 hours and +72 hours) and basic physiological assessment only. Prior to each visit, participants will be required to record a three-day habitual food and exercise diary and adhere to a prescribed low polyphenol meal the night before each laboratory visit. These measures are in place to increase the control of the study.
- Conditions
- Healthy
- Being tested
- OliPhenolia®, Taste and appearance matched placebo
- Keywords
- Hydroxytyrosol, Exercise, Inflammation, Mobility
- Medical subject headings
- Motor Activity, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OliPhenolia®Dietary supplement
Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass.
Taste and appearance matched placeboDietary supplement
Equal parts prune juice (Sunsweet California Prune Juice, Yuba City, CA, USA), diet cola (Tesco Cola, Tesco, UK) and tonic water (Tesco low calorie Indian tonic water, Tesco, UK).
| Study group | Role | What they receive |
|---|---|---|
| OliPhenolia | Experimental | Commercially available concentrated olive fruit wastewater (OliPhenolia®) will be provided in a dose relative to participant body mass. In this arm, to assess the acute effects, participants will consume an oral bolus of 1.0mg∙kg-1 olive derived hydroxytyrosol via OliPhenolia® ahead of the exercise test. Following a wash out and necessary cross-over, participants will consume two doses of 1.0mg∙kg-1 olive derived hydroxytyrosol via OliPhenolia® daily for 16 days to assess the chronic component of this study.. Receives: Dietary Supplement: OliPhenolia® |
| Placebo | Placebo comparator | In this arm, to assess the acute component, participants will consume a single oral bolus of placebo (matched for taste and appearance to OliPhenolia®) ahead of the exercise test. The volume of this will be prepared by an independent researcher to match the specific volume of OliPhenolia® required for each participant. Following a wash out and necessary cross-over, participants will consume two doses placebo (identical volume to the acute component) daily for 16 days to assess the chronic component of this study. Receives: Dietary Supplement: Taste and appearance matched placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Interleukin 6
Measured: Four days
Interleukin 1 receptor antagonist
Measured: Four days
Transforming growth factor-beta
Measured: Four days
Lactate dehydrogenase
Measured: Four days
Superoxide dismutase
Measured: Four days
Secondary outcomes (9)
Functional movement screen
The functional movement screen (FMS) will utilise the FMS test kit (Functional Movement Systems s Inc, USA) and comprise of seven movement screens described by the creators of the method: (1) "Deep squat"; (2) "Hurdle step"; (3) "In-line lunge"; (4) "Shoulder mobility"; (5) "Active straight-leg raise"; (6) "Trunk stability push-up"; And (7) "Rotary stability. This test will be utilised to correlate to day-today functional movements through the assessment of hamstring and lumbar flexibility, whole body range of motion, core strength and stability.
Measured: Four days
Counter movement jump
To assess lower body mechanical capacity and neuromuscular fatigue. Each participant will be invited to complete three repetitions of the counter movement jump with the highest repetition being recorded as the result.
Measured: Four days
Physical Readiness Questionnaire
Participants will complete the European Federation of Sports Medicine Association (EFSMA) Pre-Participation Evaluation (PPE) form for recreationally active athletes (2021) to evaluate physical readiness. Section three of this form will be repeated to subjectively measure musculoskeletal soreness surrounding the standardised exercise bout. It is important to mention, this document is merely a guideline and the 'Medical' 'Laboratory tests' and 'Exercise Capacity' sections of this document within section 3 will not be used.
Measured: Four days
Perceived Muscle soreness
Perceived muscle soreness of the lower body will be assessed using a visual analogue scale surrounding the standardised exercise protocol. Participants will subjectively rate their level of soreness during a maximal contraction of their quadriceps group by drawing an intersecting line across a continuum line extending from 0 cm (0 = no soreness) to 13 cm (13 = extreme soreness) (Buford et al. 2009). The scale is a continuous line and does not contain any segments or labels that would allow for quantification by the participant, therefore not allowing the participant to retain any perceived soreness value between testing sessions.
Measured: Four days
Pain questionnaire
The McGill Pain Questionnaire will be employed to offer a subjective measure of musculoskeletal pain. The questionnaire that provides a list of 78 descriptors of pain from which the user can pick words that can later be summed to yield a sensory, effective, and evaluative overall pain score.
Measured: Four days
Algometry
Participants perception of muscle soreness will be assessed using a simple handheld algometer (Wagner Instruments) in the non-dominant quadricep (thigh muscle). This device has been used numerous times within research studies in our laboratory. Data will be collected surrounding the standardised exercise protocol. Muscle soreness will be assessed using a standard process employing both pressure tolerance (reporting the maximum amount of pressure generating perceived discomfort that is tolerable) and secondly, pressure threshold (the minimum amount of force applied until the first verbal report of discomfort) is observed).
Measured: Four days
Range of motion at the knee and hip joint (Goiniometry)
In order to obtain an objective measure of joint angle and range of motion in the hip and knee joint, a manual goniometer will be employed. Data will be collected at baseline, after the standardised exercise protocol as well as the three days following.
Measured: Four days
Cognitive Function
The Mini Mental State Examination (MMSE), or similar, will be used to systematically and thoroughly assess mental status. It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. Assessments of cognition will take place at baseline, 24, 48 and 72 hours following the standardised exercise protocol.
Measured: Four days
Heart Rate Variability
Heart Rate Variability will be measured using a heart rate monitor to provide an objective physiological measure that is linked to the cardiovascular (CV) system and CV health.
Measured: Four days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2025
- Study start1 Jul 2025
- Primary completion30 Nov 2025
- Study completion10 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Phase 1: Participants are randomly assigned OliPhenolia or placebo (matched in taste and appearance) in a double blind manner. Following a ≥7 day wash out period, participants then cross-over to the alternate product. Phase 2: Following a further ≥7 day wash out period, participants will continue to consume the same product (OliPhenolia or placebo) for a further 16 days ahead of final exercise assessments.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Anglia Ruskin University
- Sponsor type
- University, hospital or other
- Collaborators
- Fattoria La Vialla di Gianni, Antonio e Bandino Lo Franco Soc. Agr. Sempl.
- Responsible party
- Principal investigator, Justin Roberts, Anglia Ruskin University
- Investigators
- Justin D Roberts, Professor, Principal investigator, Anglia Ruskin University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07008586
- Sponsor's protocol ID
- ETH2425-3172
- Status last verified
- Mar 2026
- First submitted
- 19 May 2025
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Roberts JD, Lillis JB, Pinto JM, Chichger H, Lopez-Samanes A, Coso JD, Zacca R, Willmott AGB. The Effect of a Hydroxytyrosol-Rich, Olive-Derived Phytocomplex on Aerobic Exercise and Acute Recovery. Nutrients. 2023 Jan 13;15(2):421. doi: 10.3390/nu15020421.
PubMed 36678293
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Acute and Chronic Effects of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Healthy Adult Humans.
- ClinicalTrials.gov ID
- NCT07008586
- Acronym / sponsor ID
- ETH2425-3172
- Conditions
- Healthy
- Keywords
- Hydroxytyrosol, Exercise, Inflammation, Mobility
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Anglia Ruskin UniversityUniversity, hospital or other
- Collaborators
- Fattoria La Vialla di Gianni, Antonio e Bandino Lo Franco Soc. Agr. Sempl.
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 10 Dec 2025 (actual)
- First posted
- 6 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research proposal follows on from previously undertaken work investigating a commercially available olive derived product (OliPhenolia®) on potential exercise / functional benefits for healthy adults. Previous research investigated a dose response bioavailability of the main polyphenol in OliPhenolia® and related metabolites. Based on this data, the current study will aim to investigate, for the first time, whether the polyphenols in the product can positively influence exercise specific inflammation which may be pertinent to improving exercise recovery and is of current scientific interest. As such this research aims to understand the short term (Phase 1) and longer term (Phase 2) use of OliPhenolia® on acute recovery from a standard exercise bout.
Research questions:
- Does an acute dose of OliPhenolia® reduce exercise associated inflammation markers and enhance functional recovery in healthy adult humans?
- Does a consecutive 16 day intake of OliPhenolia® reduce exercise associated inflammation markers and enhance functional recovery in healthy adult humans?
- Does a continued intake of OliPhenolia® during the recovery period after the exercise bout further amplify functional benefits compared experimental control?
Proposed methodology:
Phase 1 - To answer research question 1, following a randomisation procedure, participants will be allocated product (OliPhenolia®) or colour and taste matched placebo. A single serve of product (no more than 1.5 mg/kg of hydroxytyrosol (HT) via OliPhenolia®) or placebo will be provided ~40 minutes prior to a standardised exercise protocol. Resting wholeblood samples will be collected at 0 (baseline) +1, +24, +48 and +72 hours following the exercise bout to identify the impact of an acute dose of OliPhenolia® has on selected inflammatory biomarkers. This phase will be a placebo-controlled crossover design and therefore after a ≥7 day wash out period, participants will return to the exercise laboratory (Compass House Human Physiology laboratories, Anglia Ruskin University, Cambridge), supplement the alternate product and repeat the experimental protocol as outlined above.
Phase 2 - To answer research question 2, having completed Phase 1 (and following another ≥7 day wash out period), all participants will continue onto Phase 2, maintaining their previously assigned product, but this time will continue supplementation for 16 consecutive days. Phase 2 is therefore a parallel placebo-controlled design that focusses on a chronic supplementation of OliPhenolia®. Participants will consume one serve of either product or placebo twice daily for 16 days. After 16 days of supplementation participants will return to the exercise laboratory, and in the same manner as Phase 1, consume a single dose of their assigned product or placebo ~ 40 minutes prior to the standardised exercise protocol. Resting wholeblood samples will be collected following exercise at baseline, +1, +24, +48 and +72 hours.
To answer research question 3, all participants will be informed that they may be asked to consume an additional three days supplementation in a random manner (total 19 days). To limit participant burden 50 % of the experimental group (those that have been supplementing OliPhenolia®) and placebo group will continue supplementing two doses daily for the three days following the standardised exercise protocol (the three days where blood samples occur) in order to understand if a sustained course of OliPhenolia® can reduce the time taken for inflammatory mediators to return to baseline values.
Detailed description
Following the current scientific interest surrounding the application of polyphenols in an exercise domain, the primary objectives of this research will build upon previously published work investigating polyphenol rich olive fruit water by identifying the acute and chronic effect of OliPhenolia® on inflammation and functional mobility following exercise induced inflammation. For the purpose of this research, the impact on inflammation will be investigated via the measurements of biomarkers Interleukin (IL)-6, IL-1ra, and Transforming growth factor-beta. Additionally, lactate dehydrogenase (a marker of muscle damage) and superoxide dismutase (a marker of oxidative stress) will also be measured to confirm the source and impact of the exercise induced inflammation. Furthermore, for the purpose of this research, a functional movement screen, localised goniometry and algometry will be measured surrounding the standardised exercise protocol to assess the impact of OliPhenolia on functional mobility. Within this study, participants will be required to attend a pre-screening and familiarisation session followed by three separate trials. Each trial, separated by a ~7 day wash out period will consist of four visits. The first visit (estimated duration 3 hours) will include the baseline resting venepuncture blood sample (0), basic physiological, anthropometric and cognitive assessments, standardised exercise protocol, post exercise blood sample (+1 hour) and post exercise physiological assessment. The standardised exercise protocol that will take place 40 minutes after the supplementation of OliPhenolia is as follows: A maximum of six sets of 25 drop jumps wearing a weighted vest (7.5% body mass) from a height of 60 cm with a maximum 10 second interval between jumps and a 1 min passive rest between sets (modified from Kirby et al., 2011). The following three visits (estimated duration 45 minutes) will take place over the following three days and require a resting venepuncture blood sample (+24 hours, +48 hours and +72 hours) and basic physiological assessment only. Prior to each visit, participants will be required to record a three-day habitual food and exercise diary and adhere to a prescribed low polyphenol meal the night before each laboratory visit. These measures are in place to increase the control of the study.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Phase 1: Participants are randomly assigned OliPhenolia or placebo (matched in taste and appearance) in a double blind manner. Following a ≥7 day wash out period, participants then cross-over to the alternate product. Phase 2: Following a further ≥7 day wash out period, participants will continue to consume the same product (OliPhenolia or placebo) for a further 16 days ahead of final exercise assessments.
| Arm | Type | Receives |
|---|---|---|
| OliPhenolia | Experimental | Dietary Supplement: OliPhenolia®Commercially available concentrated olive fruit wastewater (OliPhenolia®) will be provided in a dose relative to participant body mass. In this arm, to assess the acute effects, participants will consume an oral bolus of 1.0mg∙kg-1 olive derived hydroxytyrosol via OliPhenolia® ahead of the exercise test. Following a wash out and necessary cross-over, participants will consume two doses of 1.0mg∙kg-1 olive derived hydroxytyrosol via OliPhenolia® daily for 16 days to assess the chronic component of this study.. |
| Placebo | Placebo comparator | Dietary Supplement: Taste and appearance matched placeboIn this arm, to assess the acute component, participants will consume a single oral bolus of placebo (matched for taste and appearance to OliPhenolia®) ahead of the exercise test. The volume of this will be prepared by an independent researcher to match the specific volume of OliPhenolia® required for each participant. Following a wash out and necessary cross-over, participants will consume two doses placebo (identical volume to the acute component) daily for 16 days to assess the chronic component of this study. |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Age ≥ 21 in line with manufacturer recommendations.
- Written informed consent.
- Willingness and ability to conform to the full protocol (please see full protocol).
- Judged by the investigator to be in good health.
- To have a pre-study health screen signed off by the lead researcher.
Key exclusion criteria (14 listed)
- Current or recent (within the last 4 weeks) engagement with a strict dietary regime i.e., vegetarian / vegan / ketogenic / paleolithic / high protein / weight loss.
- Any known issues with blood taking.
- Any known bleeding disorders.
- Any known allergy to olives, grapes, lemon, coca cola or prunes.
- Average alcohol use of <21 glasses per week for men and <14 glasses per week for women (on average for the last six months).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OliPhenolia®Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. | Dietary supplement | OliPhenolia |
| Taste and appearance matched placeboEqual parts prune juice (Sunsweet California Prune Juice, Yuba City, CA, USA), diet cola (Tesco Cola, Tesco, UK) and tonic water (Tesco low calorie Indian tonic water, Tesco, UK). | Dietary supplement | Placebo |
Primary outcome
Interleukin 6
Time frame: Four days
Interleukin 1 receptor antagonist
Time frame: Four days
Transforming growth factor-beta
Time frame: Four days
Lactate dehydrogenase
Time frame: Four days
Superoxide dismutase
Time frame: Four days
9 secondary outcomes
Functional movement screen
Time frame: Four days
Counter movement jump
Time frame: Four days
Physical Readiness Questionnaire
Time frame: Four days
Perceived Muscle soreness
Time frame: Four days
Pain questionnaire
Time frame: Four days
Algometry
Time frame: Four days
Range of motion at the knee and hip joint (Goiniometry)
Time frame: Four days
Cognitive Function
Time frame: Four days
Heart Rate Variability
Time frame: Four days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Results publication: PubMed 36678293Roberts JD, Lillis JB, Pinto JM, Chichger H, Lopez-Samanes A, Coso JD, Zacca R, Willmott AGB. The Effect of a Hydroxytyrosol-Rich, Olive-Derived Phytocomplex on Aerobic Exercise and Acute Recovery. Nutrients. 2023 Jan 13;15(2):421. doi: 10.3390/nu15020421.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Justin D Roberts, Professor principal investigator
Anglia Ruskin University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing OliPhenolia® in people with Healthy, run by Anglia Ruskin University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interleukin 6 (time frame: Four days). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07008586, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.